Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Tóm tắt
Từ khóa
Tài liệu tham khảo
Salomon B, 2001, Complexities of CD28/B7, CTLA-4 costimulatory pathways in autoimmunity and transplantation, 19, 225
Green JM, 1995, T cell costimulation through the CD28 receptor, Proc Assoc Am Physicians, 107, 41
Ferreiros‐Vidal I, 2004, Association of PDCD1 with susceptibility to systemic lupus erythematosus, evidence of population-specific effects, 50, 2590
Hayashi M, 2008, Association of an A/C single nucleotide polymorphism in programmed cell death‐ligand 1 (PD‐L1) gene with Graves' disease in Japanese patients, Eur J Endocrinol, 124, 277
Carter L, 2002, PD‐1, PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2, 32, 634
Keir ME, 2005, Programmed death‐1 (PD‐1), PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes, 175, 7372
Jenkins MK, 1987, T‐cell unresponsiveness in vivo and in vitro, fine specificity of induction and molecular characterization of the unresponsive state, 95, 113
Nishimura H, 2001, PD‐1, an inhibitory immunoreceptor involved in peripheral tolerance, 22, 265
Chikuma S, 2003, CTLA‐4 and tolerance, the biochemical point of view, 28, 241
Bennett F, 2003, Program death‐1 engagement upon TCR activation has distinct effects on costimulation and cytokine‐driven proliferation, attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses, 170, 711
Saunders PA, 2005, PD‐L2, PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion, 35, 3561
Tang Q, 2008, The Foxp3+ regulatory T cell, a jack of all trades, master of regulation, 9, 239
Anderson MS, 2005, The NOD mouse, a model of immune dysregulation, 23, 447
Chatenoud L., 2003, CD3‐specific antibody‐induced active tolerance, from bench to bedside, 3, 123
Burstein HJ, 1992, Aqueous antigens induce in vivo tolerance selectively in IL‐2‐ and IFN‐gamma‐producing (Th1) cells, J Immunol, 148, 3687, 10.4049/jimmunol.148.12.3687
Falcone M, 1998, B lymphocytes are crucial antigen‐presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice, J Immunol, 161, 1163, 10.4049/jimmunol.161.3.1163
Hwang KW, 2002, Cutting edge, targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells, 169, 633
Bluestone JA, 2006, CTLA4Ig, bridging the basic immunology with clinical application, 24, 233
Lakkis FG, 1997, Blocking the CD28‐B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL‐4, J Immunol, 158, 2443, 10.4049/jimmunol.158.5.2443
Dumont FJ., 2004, Technology evaluation, abatacept, Bristol-Myers Squibb, 6, 318
Moreland LW, 2002, Costimulatory blockade in patients with rheumatoid arthritis, a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion, 46, 1470
Weinblatt M, 2006, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs, a one-year randomized, placebo-controlled study, 54, 2807
Kremer JM, 2005, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept, twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, 52, 2263
Rozelle AL, 2007, Efficacy results from pivotal clinical trials with abatacept, Clin Exp Rheumatol, 25, S30
Tang Q, 2003, Cutting edge, CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells, 171, 3348
Urbani S, 2008, Restoration of HCV‐specific T cell functions by PD‐1/PD‐L1 blockade in HCV infection, effect of viremia levels and antiviral treatment, 48, 548
Riley JL, 2007, The road to recovery, translating PD-1 biology into clinical benefit, 28, 48
Thompson RH, 2004, Costimulatory B7‐H1 in renal cell carcinoma patients, indicator of tumor aggressiveness and potential therapeutic target, 101, 17174